Jens Mollerup
Overview
Explore the profile of Jens Mollerup including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jorgensen J, Urbanska E, Mollerup J
Transl Lung Cancer Res
. 2024 May;
13(4):940-946.
PMID: 38736494
No abstract available.
2.
Mollerup J, Jorgensen J
Cancers (Basel)
. 2023 Oct;
15(20).
PMID: 37894454
This Special Issue features contributions from leading international researchers in the field of MET (hepatocyte growth factor (HGF) receptor) biology and therapeutics [...].
3.
Jorgensen J, Mollerup J
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565287
Dysregulation of the MET tyrosine kinase receptor is a known oncogenic driver, and multiple genetic alterations can lead to a clinically relevant oncogenesis. Currently, a number of drugs targeting MET...
4.
Jorgensen J, Winther H, Askaa J, Andresen L, Olsen D, Mollerup J
Front Oncol
. 2021 Aug;
11:676939.
PMID: 34367962
The development of trastuzumab (Herceptin) was one of the most significant cancer drug development projects of the 20th century. Not only was it a scientific and medical achievement but it...
5.
Jorgensen J, Mollerup J, Yang H, Go N, Nielsen K
Ann Transl Med
. 2021 Mar;
9(3):225.
PMID: 33708852
Background: gene aberrations are found in several human cancers including gastric, ovarian and lung. In a large multinational cohort of patients with gastric/gastroesophageal junction/esophageal (G/GEJ/E) adenocarcinoma we assessed the MET...
6.
Jorgensen J, Nielsen K, Mollerup J, Jepsen A, Go N
Ann Transl Med
. 2017 Dec;
5(23):458.
PMID: 29285491
Background: The gene mesenchymal epithelial transition factor () is a proto-oncogene that encodes a transmembrane receptor with intrinsic tyrosine kinase activity known as Met or cMet. is found to be...
7.
Jorgensen J, Nielsen K, Kjaersgaard G, Jepsen A, Mollerup J
J Cancer
. 2017 Aug;
8(9):1517-1524.
PMID: 28775770
: HER2 serves as an important therapeutic target in gastroesophageal cancer. Differences in gene signal distribution patterns can be observed at the tissue level, but how it influences the amplification...
8.
Mollerup J, Henriksen U, Muller S, Schonau A
BMC Clin Pathol
. 2012 Feb;
12:3.
PMID: 22333181
Background: Chromogenic in situ hybridization (CISH) is fast becoming a well established technique for easy and sensitive determination of HER2 gene status in breast cancer. However, for the chromogenic method...
9.
Atkinson R, Mollerup J, Laenkholm A, Verardo M, Hawes D, Commins D, et al.
Arch Pathol Lab Med
. 2011 Aug;
135(8):1010-6.
PMID: 21809992
Context: New guidelines for HER2 testing have been introduced. Objectives: To evaluate the difference in HER2 assessment after introduction of new cutoff levels for both immunohistochemistry (IHC) and fluorescence in...
10.
Muirhead D, Aoun P, Powell M, Juncker F, Mollerup J
Arch Pathol Lab Med
. 2010 Jul;
134(8):1164-9.
PMID: 20670137
Context: The need for higher efficiency, maximum quality, and faster turnaround time is a continuous focus for anatomic pathology laboratories and drives changes in work scheduling, instrumentation, and management control...